- $1.02bn
- $631.10m
- $610.79m
Annual balance sheet for 10X Genomics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 664 | 587 | 430 | 389 | 393 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 51.2 | 85.3 | 104 | 115 | 87.9 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 774 | 748 | 635 | 596 | 584 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 120 | 230 | 359 | 345 | 310 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 929 | 1,019 | 1,029 | 965 | 919 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 118 | 110 | 131 | 127 | 118 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 190 | 201 | 223 | 224 | 209 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 739 | 818 | 806 | 741 | 710 |
Total Liabilities & Shareholders' Equity | 929 | 1,019 | 1,029 | 965 | 919 |
Total Common Shares Outstanding |